Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Osimertinib is currently the preferred first-line therapy in patients with non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutation and the standard second-line therapy in T790M-positive patients in progression to previous EGFR tyrosine kinase inhibitor. Osimer...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertoli, Elisa, De Carlo, Elisa, Del Conte, Alessandro, Stanzione, Brigida, Revelant, Alberto, Fassetta, Kelly, Spina, Michele, Bearz, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266773/
https://www.ncbi.nlm.nih.gov/pubmed/35805940
http://dx.doi.org/10.3390/ijms23136936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266773/
https://www.ncbi.nlm.nih.gov/pubmed/35805940
http://dx.doi.org/10.3390/ijms23136936

Ejemplares similares